Address: An der Wiek 7, 17493 Greifswald – Insel Riems,Germany
Tel: +49 38351 76-0
RIEMSER Arzneimittel AG is a company with tradition and a future.Following its demerger from the Friedrich-Loeffler-Institute Riems Island (FLI), RIEMSER Arzneimittel AG has, within a period of just a few years, evolved to become one of East Germany’s largest producers and developers of pharmaceutical products.RIEMSER has affiliated branches in such German Federal States such as Saarland, Baden-Württemberg, and Saxony as well as abroad. The company has more than 618 employees at various locations. In 2008, the group achieved sales of the order of 85,4 million euros. RIEMSER exports to more than 80 countries, including China, Russia and the U.S.A. Business transacted abroad will grow to more than 40 percent of total sales in fiscal 2009. The company prides itself on a well-diversified portfolio, which encompasses the areas human, veterinary, and dental. Its core competencies focus on oncology and dermatology as well as on dental products and anti-infectives, in veterinary, the emphasis is on animal vaccines.
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
